U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H19NO
Molecular Weight 241.3282
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LITOXETINE

SMILES

C(OC1CCNCC1)C2=CC3=C(C=CC=C3)C=C2

InChI

InChIKey=MJJDYOLPMGIWND-UHFFFAOYSA-N
InChI=1S/C16H19NO/c1-2-4-15-11-13(5-6-14(15)3-1)12-18-16-7-9-17-10-8-16/h1-6,11,16-17H,7-10,12H2

HIDE SMILES / InChI
Litoxetine is a selective serotonin (5-HT) reuptake inhibitor (SSRI) and mixed serotonin agonist-antagonist, which makes it particularly appropriate for treating continence dysfunctions. Litoxetine at concentrations without antimuscarinic properties (10 nM-1 microM) caused concentration-dependent relaxations in the rat isolated oesophageal muscularis mucosae, which reduced carbachol tone up to 37%. Higher litoxetine concentrations (3 microM-300 microM) were associated with marked relaxation up to the abolition of carbachol tone. The antimuscarinic activity of litoxetine, previously demonstrated in the isolated guinea-pig intestine, played a role in the rat isolated oesophageal muscularis mucosae at concentrations greater than 1 microM. The 5-HT-releasing action of litoxetine could account for the potentation by litoxetine of 5-HT-induced relaxation in tissues from untreated rats, which was reversed by pCPA treatment. Litoxetine is in phase II clinical trial for the treatment of urinary incontinence.

Approval Year

PubMed

PubMed

TitleDatePubMed
Advances in sodium-ion coupled biogenic amine transporters.
1992
Activity of litoxetine and other serotonin uptake inhibitors in the tail suspension test in mice.
1992 May
Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties.
1993 Mar 2
EEG profile of litoxetine after single and repeated administration in healthy volunteers.
1994 Feb
Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.
2009 Oct 15

Sample Use Guides

2.5 mg, 5 mg, 10 mg, 25 mg or placebo twice daily on days 1-4 and once on day 5
Route of Administration: Oral
Name Type Language
LITOXETINE
INN  
INN  
Official Name English
4-(2-NAPHTHYLMETHOXY)PIPERIDINE
Systematic Name English
litoxetine [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C265
Created by admin on Fri Dec 15 15:51:41 GMT 2023 , Edited by admin on Fri Dec 15 15:51:41 GMT 2023
Code System Code Type Description
INN
6662
Created by admin on Fri Dec 15 15:51:41 GMT 2023 , Edited by admin on Fri Dec 15 15:51:41 GMT 2023
PRIMARY
EVMPD
SUB08536MIG
Created by admin on Fri Dec 15 15:51:41 GMT 2023 , Edited by admin on Fri Dec 15 15:51:41 GMT 2023
PRIMARY
CAS
86811-09-8
Created by admin on Fri Dec 15 15:51:41 GMT 2023 , Edited by admin on Fri Dec 15 15:51:41 GMT 2023
PRIMARY
FDA UNII
9980ST005G
Created by admin on Fri Dec 15 15:51:41 GMT 2023 , Edited by admin on Fri Dec 15 15:51:41 GMT 2023
PRIMARY
ChEMBL
CHEMBL471036
Created by admin on Fri Dec 15 15:51:41 GMT 2023 , Edited by admin on Fri Dec 15 15:51:41 GMT 2023
PRIMARY
WIKIPEDIA
Litoxetine
Created by admin on Fri Dec 15 15:51:41 GMT 2023 , Edited by admin on Fri Dec 15 15:51:41 GMT 2023
PRIMARY
NCI_THESAURUS
C66021
Created by admin on Fri Dec 15 15:51:41 GMT 2023 , Edited by admin on Fri Dec 15 15:51:41 GMT 2023
PRIMARY
SMS_ID
100000082545
Created by admin on Fri Dec 15 15:51:41 GMT 2023 , Edited by admin on Fri Dec 15 15:51:41 GMT 2023
PRIMARY
MESH
C057048
Created by admin on Fri Dec 15 15:51:41 GMT 2023 , Edited by admin on Fri Dec 15 15:51:41 GMT 2023
PRIMARY
DRUG BANK
DB15038
Created by admin on Fri Dec 15 15:51:41 GMT 2023 , Edited by admin on Fri Dec 15 15:51:41 GMT 2023
PRIMARY
EPA CompTox
DTXSID30235828
Created by admin on Fri Dec 15 15:51:41 GMT 2023 , Edited by admin on Fri Dec 15 15:51:41 GMT 2023
PRIMARY
PUBCHEM
65650
Created by admin on Fri Dec 15 15:51:41 GMT 2023 , Edited by admin on Fri Dec 15 15:51:41 GMT 2023
PRIMARY